Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors

PURPOSE: We explored the clinical and genomic characteristics of hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (MBC) after progression on cyclin-dependent kinase 4 and 6 inhibitors (CDK4 and 6i) ± endocrine therapy (ET) to understand potential resistance mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Xi, Chen, Yongmei, Beyrer, Julie, Nash Smyth, Emily, Morato Guimaraes, Claudia, Litchfield, Lacey M., Bowman, Lee, Lawrence, Garreth W., Aggarwal, Amit, Andre, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472108/
https://www.ncbi.nlm.nih.gov/pubmed/37289194
http://dx.doi.org/10.1158/1078-0432.CCR-22-3843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472108/
https://www.ncbi.nlm.nih.gov/pubmed/37289194
http://dx.doi.org/10.1158/1078-0432.CCR-22-3843

Ejemplares similares